Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
Menée sur 361 patientes atteintes d'un cancer de l'ovaire résistant aux sels de platine, cet essai de phase IIII évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du bévacizumab en complément d'une chimiothérapie
Since bevacizumab was first reported to have single-agent activity in ovarian cancer, multiple studies have sought to establish whether combining bevacizumab with chemotherapy might improve the outcome of patients with newly diagnosed or recurrent disease. In the article that accompanies this editorial, Pujade- Lauraine et al report the results of AURELIA, a randomized trial comparing the effectiveness of chemotherapy combined with bevacizumab (investigator’s choice of once-per-week paclitaxel, pegylated liposomal doxorubicin [PLD], or topotecan) to that of chemotherapy alone in recurrent platinum-resistant ovarian cancer. In a companion article, Stockler et al report the results of patient-related outcomes (PROs) in AURELIA, evaluating abdominal/ GI PROs in patients receiving chemotherapy combined with bevacizumab as compared with chemotherapy alone...
Journal of Clinical Oncology , éditorial en libre accès, 2014